Skip to content
  • About
  • Team
  • Clinical Trials
  • KRN-101
  • Investing
  • Press & Updates
  • Contact
Menu
  • About
  • Team
  • Clinical Trials
  • KRN-101
  • Investing
  • Press & Updates
  • Contact
CSE: ABRT • FSE: VB50
CSE: ABRT
ABRT
  • About
  • Team
  • Clinical Trials
  • KRN-101
  • Investing
  • Press & Updates
  • Contact
Menu
  • About
  • Team
  • Clinical Trials
  • KRN-101
  • Investing
  • Press & Updates
  • Contact
CSE: ABRT • FSE: VB50
CSE: ABRT
ABRT
You are currently viewing Persisting decreases in state and trait anxiety post-psilocybin: A naturalistic, observational study among retreat attendees

Persisting decreases in state and trait anxiety post-psilocybin: A naturalistic, observational study among retreat attendees

  • Post author:Olly PP
  • Post published:March 2, 2022
  • Post category:Industry News
Tags: Industry Media

Read more articles

Previous PostHarvard takes a new trip into the world of psychedelic drugs
Next PostBrexit Britain becomes unlikely psychedelic haven as Albert Labs IPOs

You Might Also Like

Read more about the article How psilocybin, the psychedelic in mushrooms, may rewire the brain to ease depression, anxiety and more

How psilocybin, the psychedelic in mushrooms, may rewire the brain to ease depression, anxiety and more

June 11, 2022
Read more about the article Can Psilocybin Challenge Our Pharmaceutical Dependence?

Can Psilocybin Challenge Our Pharmaceutical Dependence?

October 12, 2022
Read more about the article Study finds psilocybin repairs brain cell damage associated with depression

Study finds psilocybin repairs brain cell damage associated with depression

July 21, 2021

Recent Posts

  • Expansion of Drug Discovery and a Promising Pipeline
  • Albert Labs Announces Private Placement
  • Letter of Intent (LOI) for First-In-Human studies with iNGENÅ« CRO
  • Albert Labs Provides Corporate Update
  • Psychedelic Therapy isn’t Fringe Anymore

Recent Comments

    Innovative mental health medicines for patients with unmet needs

    • Legal Disclaimer
    • Privacy Policy
    • Modern Slavery Statement
    • Cookie Policy
    • Legal Disclaimer
    • Privacy Policy
    • Modern Slavery Statement
    • Cookie Policy

    © 2022 Albert Labs. All Rights Reserved

    • About
    • Team
    • Clinical Trials
    • KRN-101
    • Investing
    • Press & Updates
    • Contact
    • About
    • Team
    • Clinical Trials
    • KRN-101
    • Investing
    • Press & Updates
    • Contact
    Twitter Linkedin Youtube Envelope
    CSE:ABRT
    FSE: VB50
    CSE:ABRT
    FSE: VB50

    About Albert Labs

    We are a pharmaceutical company leveraging our drug development and clinical research expertise to accelerate the development of highly effective mental health medicines.

    If you would like support or more information around making an investment, please contact investing@albertlabs.com

    Twitter Linkedin Youtube Envelope

    Complete this form to receive corporate updates and further details on how to invest in Albert Labs. By completing this form, you agree to our privacy policy.

    • This field is for validation purposes and should be left unchanged.

    Twitter
    Youtube
    Linkedin
    Instagram
    Envelope
    Twitter
    Youtube
    Linkedin
    Instagram
    Envelope

    By completing this form you agree to our privacy policy. You will be sent corporate updates and further details including how to invest in Albert Labs.